{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-242959","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.568224+00:00","generated_at":"2026-05-17T03:16:35.748887+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Disc Medicine reports $615.9M cash; bitopertin NDA submitted for accelerated review (CNPV)","bullets":["Preliminary unaudited cash, equivalents and marketable securities of ~$615.9M as of September 30, 2025.","NDA for bitopertin in EPP submitted Sept 29, 2025; awarded FDA CNPV for 1-2 month review; potential US approval late 2025/early 2026.","Phase 2 RALLY-MF trial of DISC-0974 in anemia of MF: initial data by year-end 2025, topline data in 2026.","DISC-3405 Phase 2 PV topline data expected 2026; Phase 1b in sickle cell disease by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-242959","json":"https://secwatch.observer/filing/0001193125-25-242959.json","markdown":"https://secwatch.observer/filing/0001193125-25-242959.md","text":"https://secwatch.observer/filing/0001193125-25-242959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/0001193125-25-242959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312525242959/d272031d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:16:35.748887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}